Date published: 2026-5-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

FLJ39531 Inhibitors

FLJ39531 inhibitors represent a class of chemical compounds designed and developed primarily for their ability to modulate the activity of the FLJ39531 protein. FLJ39531, also known as C6orf106 or FAM198B, is a relatively less characterized protein whose exact function and role in cellular processes remain under investigation. Researchers have identified this protein as a target for pharmacological intervention due to its association with various biological pathways and cellular functions. As such, FLJ39531 inhibitors are chemical agents designed to interact with this specific protein, either by binding to it directly or by affecting downstream signaling pathways in which FLJ39531 participates.

The development and study of FLJ39531 inhibitors fall within the broader field of drug discovery and chemical biology. Scientists employ a variety of techniques, such as high-throughput screening and structure-based design, to identify and optimize compounds with inhibitory activity against FLJ39531. These inhibitors are essential tools in biological research, enabling scientists to explore the function of FLJ39531 and its implications in cellular processes. While the precise biological significance of FLJ39531 inhibition is still being elucidated, this chemical class plays a vital role in advancing our understanding of the protein's biology and its relevance to human health and disease.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$26.00
$119.00
$213.00
27
(1)

Tyrosine kinase inhibitor that targets BCR-ABL, c-KIT, and PDGFR, used primarily in CML and GISTs.

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$63.00
$114.00
$218.00
$349.00
74
(2)

tyrosine kinase inhibitor used in non-small cell lung cancer with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

mTOR inhibitor that binds to FKBP12 and inhibits the mTORC1 complex, affecting cell growth and proliferation.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$114.00
$166.00
$947.00
19
(1)

MEK inhibitor that interferes with the RAS/RAF/MEK/ERK pathway, used in melanoma.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$117.00
$423.00
11
(1)

BRAF inhibitor used in metastatic melanoma with BRAF V600E mutation, inhibiting the MAPK pathway.

Palbociclib

571190-30-2sc-507366
50 mg
$321.00
(0)

CDK4/6 inhibitor that halts cell cycle progression by blcoking phosphorylation of retinoblastoma protein, used in breast cancer.

Bortezomib

179324-69-7sc-217785
sc-217785A
2.5 mg
25 mg
$135.00
$1085.00
115
(2)

Proteasome inhibitor that blokcs degradation of ubiquitinated proteins, affecting cell cycle and survival, used in multiple myeloma.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$210.00
$305.00
$495.00
10
(1)

PARP inhibitor studied in the research of ovarian and breast cancers with BRCA1/2 mutations, blocking DNA repair.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$57.00
$100.00
$250.00
129
(3)

Multi-kinase inhibitor that targets RAF kinases, VEGFR, and PDGFR, used in renal and hepatocellular carcinoma.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$118.00
$337.00
$520.00
$832.00
$1632.00
10
(0)

BCL-2 inhibitor that promotes apoptosis by blocking the binding of pro-apoptotic proteins, used in chronic lymphocytic leukemia.